MMED vs TNDM
MMED: MiniMed is a dedicated diabetes technology company providing automated insulin delivery and smart injection systems to improve glycemic control for patients worldwide. TNDM: Tandem Diabetes Care provides advanced, consumer-focused automated insulin delivery systems designed to simplify diabetes management.
Side-by-side fundamentals
| Metric | MMED | TNDM | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $19.80 | $15.68 | |
| Market cap | $5.6B | $1.1B | |
| Net margin | -10.7% | -20.2% | MMED higher |
| Gross margin | +54.2% | +53.8% | MMED higher |
| Operating margin | -6.1% | -18.5% | MMED higher |
| ROE | -9.2% | -131.9% | MMED higher |
| ROA | -7.2% | -23.2% | MMED higher |
| Debt / equity as of 2026-09-03 | 0.00 | 4.66 | MMED lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +4.0% | |
| Revenue CAGR (3y) SEC XBRL | +12.1% | +8.2% | MMED higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.84 | 1.11 | |
| 1-year return as of 2026-10-08 close | n/a | +2.2% |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.